Looking to improve the integrity of the U.S. drug supply chain and patient safety, the FDA Tuesday put drug companies on notice that it will inactivate listing records that are outdated or inaccurate as of Sept. 12. Drugs with inactivated listings cannot be legally marketed in the U.S.